EP. 1: An overview on KRAS+ mutated lung adenocarcinoma
Background on KRAS mutations in lung adenocarcinoma, including the prevalence, prognosis, and challenges in treating patients with NSCLC.
EP. 2: Selecting Frontline Therapy for KRAS+ mutated lung adenocarcinoma
Cinical trial data and guidelines on optimal first-line regimens for metastatic KRAS mutated lung adenocarcinoma.
EP. 3: KRYSTAL-1: Review of Key Efficacy Data
An overview of the role of KRAS G12C inhibitors in the second line and beyond for KRAS G12C mutated NSCLCs after progression on platinum-based chemotherapy.
EP. 4: Comparing the Efficacy and Safety of KRAS G12C inhibitors for patients with NSCLC
Clinical trial efficacy and safety data between KRAS G12C inhibitors that inform initial treatment selection for patients with NSCLC.
EP. 5: Strategies for monitoring and mitigating hepatotoxicity with KRAS G12C inhibitors
An overview of recognizing and managing common immune-related and systemic adverse events with immune checkpoint inhibitors, chemotherapy and KRAS targeted therapies in NSCLC.
EP. 6: Key Considerations for Treating patients with NSCLC using KRAS inhibitors
Other considerations between KRAS targeting treatments in patients with KRAS+ mutated NSCLC.
2 Commerce Drive Cranbury, NJ 08512